55 completed. 55 Phase 2, 9 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 55 | Completed 55 |
| Phase 1 | 9 | Completed 9 |
| Phase 3 | 7 | Completed 7 |
Follow Atrophy: new trials by email Literature Review of Atrophy trials Research Report on Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Pharmaconutrition Therapy for Myosteatosis, Sarcopenia, and Prognosis in Gastric Cancer Patients Pharmaconutrition - Myosteatosis, Sarcopenia | Phase 2 | Completed | Biruni University | 40 | 2024-10-16 | 2026-03-12 |
| Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt Enobosarm, Semaglutide - Muscle Loss, Obesity | Phase 2 | Completed | Veru Inc. | 168 | 2024-04-29 | 2025-09-17 |
| Pediatric Oncology Nutrition Intervention Trial Oral Nutrition Supplement, Tube Feed, Cyproheptadine - Pediatric Cancer, Nutrition Related Cancer | Phase 2 / Phase 3 | Completed | Corey Hawes | 20 | 2024-01-31 | 2026-10-08 |
| Effect Of Ophiochepalus Striatus Extract On Serum IGF-1 And IL-6 Levels In Elderly Patients With Sarcopenia Ophiochepalus striatus extract, Placebo - Sarcopenia, Geriatric | Phase 2 / Phase 3 | Completed | Universitas Sriwijaya | 80 | 2023-05-01 | 2025-01-31 |
| Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI) Ursolic Acid, Strength Training - Spinal Cord Injuries, Tetraplegia | Phase 2 | Completed | University of Miami | 10 | 2023-03-27 | 2025-05-21 |
| Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. IMM01-STEM - Muscle Atrophy | Phase 1 / Phase 2 | Completed | Immunis, Inc. | 13 | 2022-09-13 | 2026-09-09 |
| Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty MYMD-1 600MG, MYMD-1 750mg, MYMD-1 900mg - Sarcopenia, Frailty | Phase 2 | Completed | TNF Pharmaceuticals, Inc. | 40 | 2022-02-01 | 2023-10-30 |
| Growth Hormone in Decompensated Liver Cirrhosis Growth Hormone - Liver Cirrhosis, Fibrosis | Phase 2 / Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 96 | 2022-02-01 | 2025-12-16 |
| A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia LPCN 1148, Placebo - Liver Cirrhosis, Sarcopenia | Phase 2 | Completed | Lipocine Inc. | 30 | 2021-11-30 | 2024-03-15 |
| Electrical Stimulation for Critically Ill Post-Covid-19 Patients Electrical Stimulation, Electrical Stimulation - Sham - COVID-19, Muscle Atrophy | Phase 2 | Completed | Baylor College of Medicine | 19 | 2021-08-18 | 2023-03-07 |
| Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS) Zoledronic Acid, Placebo - Bone Loss, Muscle Atrophy | Phase 2 | Completed | Stinus Gadegaard Hansen | 59 | 2021-02-20 | 2026-06-01 |
| An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency doxecitine and doxribtimine - Thymidine Kinase 2 Deficiency | Phase 2 | Completed | UCB BIOSCIENCES, Inc. | 47 | 2019-07-05 | 2026-09-08 |
| An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy SRK-015 - Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | Phase 2 | Completed | Scholar Rock, Inc. | 58 | 2019-04-22 | 2024-12-02 |
| Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease CoQ10, Nicotinamide riboside, Placebo - Chronic Kidney Disease, Sarcopenia | Phase 2 | Completed | University of Washington | 26 | 2018-11-14 | 2023-01-10 |
| Effect of High Protein Diet in Stroke Patients With Low Muscle Mass high protein diet, normal protein diet - Ischemic Stroke, Diet, Healthy | Phase 2 | Completed | Chang Gung Memorial Hospital | 110 | 2017-12-15 | 2023-03-30 |
| The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity Oxytocin nasal spray, Placebo nasal spray - Obesity, Sarcopenic Obesity | Phase 1 / Phase 2 | Completed | Sara Espinoza | 23 | 2017-09-22 | 2021-10-22 |
| A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT) BIO101, Placebo - Sarcopenia, Gait Disorders in Old Age | Phase 2 | Completed | Biophytis | 233 | 2017-02-07 | 2024-10-01 |
| Feasibility of Home vs. Hospital Based Resistance Training for Advanced Cancer Patients Resistance training - Advanced Cancer | Phase 2 | Completed | King's College London | 15 | 2016-07-01 | 2017-03-07 |
| Trial of Oral Glutamine on Mitochondrial Function in CKD First Intervention (14 days), Washout (3 weeks), Second Intervention (14 days) - Cardiovascular Disease, Sarcopenia | Phase 2 | Completed | University of Washington | 11 | 2016-02-25 | 2022-07-14 |
| A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study bimagrumab, Placebo - Sarcopenia | Phase 2 | Completed | Novartis Pharmaceuticals | 160 | 2015-07-22 | 2020-06-16 |
Showing 20 of 55. Sign in to see all of them.
Muscular Atrophy (27) · Sarcopenia (26) · Frailty (5) · Muscle Weakness (4) · Obesity (3) · Weight Loss (3) · Amyotrophic Lateral Sclerosis (2) · Cachexia (2) · Insulin Resistance (2) · Liver Cirrhosis (2) · Lymphoma, Non-Hodgkin (2) · Neoplasms (2) · Osteoporosis (2) · Renal Insufficiency, Chronic (2)
Pathological Conditions, Signs and Symptoms (55) · Pathological Conditions, Anatomical (54) · Neurologic Manifestations (51) · Signs and Symptoms (51) · Nervous System Diseases (50) · Neuromuscular Manifestations (49) · Muscular Atrophy (23) · Pathologic Processes (13) · Nutritional and Metabolic Diseases (12) · Musculoskeletal Diseases (9) · Metabolic Diseases (8) · Body Weight (7) · Muscular Diseases (6) · Body Weight Changes (5)
bimagrumab (5) · Resistance Training (3) · Amino Acids, Essential (2) · Growth Hormone (2) · Leucine (2) · Testosterone (2) · mecobalamin (2) · ostarine (2) · Acetylcysteine (1) · Alanine (1) · Anastrozole (1) · Aromatase Inhibitors (1) · Caseins (1) · Clobetasol (1) · Cyproheptadine (1)
Novartis Pharmaceuticals (5) · Eisai Co., Ltd. (2) · Maastricht University Medical Center (2) · National Institute on Aging (NIA) (2) · University of Washington (2) · VA Office of Research and Development (2) · Assistance Publique - Hôpitaux de Paris (1) · Baylor College of Medicine (1) · Biophytis (1) · Biruni University (1) · Chang Gung Memorial Hospital (1) · Corey Hawes (1) · Eli Lilly and Company (1) · Federal University of São Paulo (1) · GTx (1)
United States (34) · France (8) · Japan (7) · Spain (7) · Belgium (6) · Netherlands (6) · Denmark (5) · Australia (4) · Switzerland (4) · Taiwan (4) · United Kingdom (4) · Canada (3) · Czechia (3) · Germany (3) · Russia (3)
Jeremy Walston, MD (2) · Kazunori Saeki (2) · Luc JC van Loon, PhD (2) · Aino F Jonasson, MD (1) · Anne R. Cappola, M.D.,Sc.M. (1) · Baback Roshanravan, MD (1) · Bess Dawson-Hughes, M.D. (1) · Bryan Kestenbaum, MD (1) · Chris Winkelman, PhD (1) · Christopher L Mendias, PhD, ATC (1) · Corey J Hawes, DCN, RD, CSO, CNSC, LD (1)
PMID 19106243, PMID 19321567, PMID 19446324, PMID 20739716, PMID 21389329, PMID 21543538, PMID 21631380, PMID 21753869, PMID 23499390, PMID 23732550, PMID 24012740, PMID 24326421, PMID 25923482, PMID 25973477, PMID 25982504, PMID 26733251, PMID 26829246, PMID 26950683, PMID 26980371, PMID 27999607, PMID 28508697, PMID 28842733, PMID 29211866, PMID 30095981, PMID 30280129, PMID 30636701, PMID 31343947, PMID 31397289, PMID 32452208, PMID 32792420, PMID 33074327, PMID 33246973, PMID 34029521, PMID 35511890, PMID 36098133, PMID 36209245, PMID 36905161, PMID 37159264, PMID 38330285, PMID 38525752, PMID 39513970, PMID 39847432, PMID 41177144, PMID 41475066
2015 (1), 2018 (1), 2023 (1), K23DK099442 (1), P30AG021334 (1), P30AG028740 (1), R01AG018169 (1), R01AG046401 (1), R01AR060261 (1), R01DK101509 (1), UL1TR001998 (1)